
BiondVax Pharmaceuticals Ltd. – NASDAQ:BVXV
BiondVax Pharmaceuticals Ltd. stock price monthly change
BiondVax Pharmaceuticals Ltd. stock price quarterly change
BiondVax Pharmaceuticals Ltd. stock price yearly change
BiondVax Pharmaceuticals Ltd. key metrics
Market Cap | 4.96M |
Enterprise value | 35.86M |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | -2.59 |
Price/Sales | N/A |
Price/Book | 1.16 |
PEG ratio | -0.05 |
EPS | N/A |
Revenue | N/A |
EBITDA | -5.00M |
Income | 7.78M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiondVax Pharmaceuticals Ltd. stock price history
BiondVax Pharmaceuticals Ltd. stock forecast
BiondVax Pharmaceuticals Ltd. financial statements
Sep 2022 | 0 | 9.79M | |
---|---|---|---|
Dec 2022 | 0 | 5.59M | |
Mar 2023 | 2.01M | -3.84M | -190.67% |
Jun 2023 | 0 | -3.76M |
2022-06-01 | -4 | -2 |
---|---|---|
2022-08-25 | -0.40005 | -2.1 |
2022-11-30 | -0.006 | 0.06 |
2023-04-17 | -0.3 | -0.3 |
Sep 2022 | 74717000 | 65.35M | 87.47% |
---|---|---|---|
Dec 2022 | 27067000 | 28.82M | 106.5% |
Mar 2023 | 23292000 | 28.10M | 120.65% |
Jun 2023 | 19897000 | 27.00M | 135.74% |
Jun 2022 | -10.40M | -84K | -468K |
---|---|---|---|
Dec 2022 | 15.85M | -483K | -25.80M |
Mar 2023 | -3.05M | -6K | 0 |
Jun 2023 | -2.87M | -377K | 0 |
BiondVax Pharmaceuticals Ltd. alternative data
Aug 2023 | 33 |
---|---|
Sep 2023 | 33 |
Oct 2023 | 33 |
Nov 2023 | 33 |
Dec 2023 | 33 |
Jan 2024 | 33 |
Feb 2024 | 33 |
Mar 2024 | 33 |
Apr 2024 | 33 |
May 2024 | 33 |
Jun 2024 | 33 |
Jul 2024 | 33 |
BiondVax Pharmaceuticals Ltd. other data
Patent |
---|
Application Filling date: 27 Aug 2019 Issue date: 2 Jan 2020 |
Quarter | Transcript |
---|---|
Q4 2021 4 Apr 2022 | Q4 2021 Earnings Call Transcript |
-
When is BiondVax Pharmaceuticals Ltd.'s next earnings date?
Unfortunately, BiondVax Pharmaceuticals Ltd.'s (BVXV) next earnings date is currently unknown.
-
Does BiondVax Pharmaceuticals Ltd. pay dividends?
No, BiondVax Pharmaceuticals Ltd. does not pay dividends.
-
How much money does BiondVax Pharmaceuticals Ltd. make?
BiondVax Pharmaceuticals Ltd. has a market capitalization of 4.96M. BiondVax Pharmaceuticals Ltd. made a loss 531K US dollars in net income (profit) last year or -$0.3 on an earnings per share basis.
-
What is BiondVax Pharmaceuticals Ltd.'s stock symbol?
BiondVax Pharmaceuticals Ltd. is traded on the NASDAQ under the ticker symbol "BVXV".
-
What is BiondVax Pharmaceuticals Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BiondVax Pharmaceuticals Ltd.?
Shares of BiondVax Pharmaceuticals Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does BiondVax Pharmaceuticals Ltd. have?
As Jul 2024, BiondVax Pharmaceuticals Ltd. employs 33 workers.
-
When BiondVax Pharmaceuticals Ltd. went public?
BiondVax Pharmaceuticals Ltd. is publicly traded company for more then 10 years since IPO on 12 May 2015.
-
What is BiondVax Pharmaceuticals Ltd.'s official website?
The official website for BiondVax Pharmaceuticals Ltd. is biondvax.com.
-
How can i contact BiondVax Pharmaceuticals Ltd.?
BiondVax Pharmaceuticals Ltd. can be reached via phone at +972 8 930 2529.
BiondVax Pharmaceuticals Ltd. company profile:

BiondVax Pharmaceuticals Ltd.
biondvax.comNASDAQ
33
Biotechnology
Healthcare
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Jerusalem,
CIK: 0001611747
ISIN: US09073Q1058
CUSIP: 09073Q105